Article
Oncology
MacLean S. Hall, Jamie K. Teer, Xiaoqing Yu, Holly Branthoover, Sebastian Snedal, Madeline Rodriguez-Valentin, Luz Nagle, Ellen Scott, Ben Schachner, Patrick Innamarato, Amy M. Hall, Jamie Blauvelt, Carolyn J. Rich, Allison D. Richards, Jake Ceccarelli, T. J. Langer, Sean J. Yoder, Matthew S. Beatty, Cheryl A. Cox, Jane L. Messina, Daniel Abate-Daga, James J. Mule, John E. Mullinax, Amod A. Sarnaik, Shari Pilon-Thomas
Summary: This study highlights the importance of neoantigen-specific CD4(+)T cells within tumor-infiltrating lymphocytes (TILs) as a potent source of tumor-specific effectors. The findings suggest that these CD4(+)T cells play a significant role in antitumor immunity and should be included in future adoptive cell therapy (ACT) protocols to improve treatment efficacy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Anders Handrup Kverneland, Christopher Aled Chamberlain, Troels Holz Borch, Morten Nielsen, Sofie Kirial Mork, Julie Westerlin Kjeldsen, Cathrine Lund Lorentzen, Lise Pyndt Jorgensen, Lene Buhl Riis, Christina Westmose Yde, Ozcan Met, Marco Donia, Inge Marie Svane
Summary: This study demonstrated high success rates of TIL expansion and tumor regressions in multiple solid cancer types when combining TIL ACT with CPIs. In vitro tumor reactivity was positively associated with treatment outcomes.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Chantal Saberian, Rodabe N. Amaria, Amer M. Najjar, Laszlo G. Radvanyi, Cara L. Haymaker, Marie-Andree Forget, Roland L. Bassett, Silvana C. Faria, Isabella C. Glitza, Enrique Alvarez, Sapna Parshottam, Victor Prieto, Gregory Lizee, Michael K. Wong, Jennifer L. McQuade, Adi Diab, Cassian Yee, Hussein A. Tawbi, Sapna Patel, Elizabeth J. Shpall, Michael A. Davies, Patrick Hwu, Chantale Bernatchez
Summary: The combination of adoptive transfer of tumor-infiltrating lymphocytes (TIL) and dendritic cells (DC) did not show significant difference in the persistence of MART-1-specific TIL compared to TIL therapy alone. Although more patients showed clinical response to TIL+DC therapy, the study was not powered to resolve differences between the two groups.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Michael G. Fradley, Rongras Damrongwatanasuk, Sanjay Chandrasekhar, Mohammed Alomar, Kevin E. Kip, Amod A. Sarnaiks
Summary: Adoptive cellular therapy with tumor-infiltrating lymphocytes has shown to be effective in treating unresectable stage III/IV metastatic melanoma, despite common cardiovascular toxicities. Research is needed to better understand the mechanisms and prevention strategies to help clinicians manage these complications and reduce risks, as they do not seem to significantly impact patient survival.
JOURNAL OF IMMUNOTHERAPY
(2021)
Article
Oncology
Naama Margolis, Hanna Moalem, Tomer Meirson, Gilli Galore-Haskel, Ettai Markovits, Erez N. Baruch, Bella Vizel, Avner Yeffet, Julia Kanterman-Rifman, Assaf Debby, Michal J. Besser, Jacob Schachter, Gal Markel
Summary: The interaction between melanoma cells and T cells can enhance the chemotaxis of new T cells. ADAR1-p150 expression is correlated with immune infiltration and can be induced by immunotherapy. ADAR1 regulates T cell migration through the secretion of chemokines.
CANCER IMMUNOLOGY RESEARCH
(2022)
Article
Oncology
Ikuko Hirai, Takeru Funakoshi, Hajime Kamijuku, Keitaro Fukuda, Mariko Mori, Masatoshi Sakurai, Yuya Koda, Jun Kato, Takehiko Mori, Naohide Watanabe, Shinobu Noji, Tomonori Yaguchi, Takashi Iwata, Shigeki Ohta, Tomonobu Fujita, Ryuji Tanosaki, Makoto Handa, Shinichiro Okamoto, Masayuki Amagai, Yutaka Kawakami
Summary: The study evaluated the feasibility of adoptive cell therapy using tumor-infiltrating lymphocytes in Japanese melanoma patients who failed immune-checkpoint inhibitor therapy. Different immunostimulatory and immunosuppressive factors were identified that may influence the efficacy of the therapy. Results showed that the TIL-ACT regimen was suitable for Japanese patients with melanoma, with further studies needed to explore immune-resistant mechanisms.
Article
Oncology
Parin Shah, Marie-Andree Forget, Meredith L. Frank, Peixin Jiang, Donastas Sakellariou-Thompson, Lorenzo Federico, Roohussaba Khairullah, Chantal Alexia Neutzler, Ignacio Wistuba, Chi-Wan B. Chow, Yan Long, Junya Fujimoto, Shiaw-Yih Lin, Anirban Maitra, Marcelo Negrao, Kyle Gregory Mitchell, Annikka Weissferdt, Ara A. Vaporciyan, Tina Cascone, Jack A. Roth, Jianjun Zhang, Boris Sepesi, Don L. Gibbons, John Heymach, Cara L. Haymaker, Daniel J. McGrail, Alexandre Reuben, Chantale Bernatchez
Summary: This preclinical study successfully expanded tumor-infiltrating lymphocytes (TIL) from non-small cell lung cancer (NSCLC) using an improved culture method (TIL 3.0), which enriched for CD8(+) TIL. The TIL 3.0 method shows promise as a testing platform for TIL-ACT approaches in NSCLC.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Samantha M. Fix, Marie-Andree Forget, Donastas Sakellariou-Thompson, Yunfei Wang, Tamara M. Griffiths, Minjung Lee, Cara L. Haymaker, Ana Lucia Dominguez, Rafet Basar, Christopher Reyes, Sanjay Kumar, Larissa A. Meyer, Patrick Hwu, Chantale Bernatchez, Amir A. Jazaeri
Summary: In this study, we optimized CRISPR/Cas9-mediated knockout of TGF-beta receptor 2 (TGFBR2) in patient-derived ovarian cancer TIL. TGFBR2 knockout TIL showed resistance to immunosuppression and improved cytotoxicity. This lays the groundwork for clinical translation of CRISPR-modified TIL for the treatment of ovarian cancer and other solid cancers.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Julia Karbach, Dragan Kiselicki, Kathrin Brand, Claudia Wahle, Evgueni Sinelnikov, Dirk Gustavus, Hans Hoffmeister, Hans-Bernd Prisack, Akin Atmaca, Elke Jaeger
Summary: Adoptive transfer of autologous tumor-specific lymphocytes in conjunction with IL-2 and immune-checkpoint blockade led to complete and durable tumor remission in a patient with metastatic hormone-refractory NY-ESO-1 expressing prostate cancer. The treatment resulted in a decrease of tumor-driven NY-ESO-1 serum antibody and prostate-specific antigen, demonstrating the effectiveness of this method for advanced malignancies.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Chaoting Zhang, Yizhe Sun, Shance Li, Luyan Shen, Xia Teng, Yefei Xiao, Nan Wu, Zheming Lu
Summary: The study found that restoring autophagic flux of exhausted TILs through spermidine treatment can enhance the diversity of TCR repertoire, reduce the expression of inhibitory immunoreceptors (PD1, TIM3, or LAG3), improve proliferation and effector functions, leading to superior in vitro and in vivo antitumor activity.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Biotechnology & Applied Microbiology
Yahui Zhu, Jing Zhou, Lijing Zhu, Wenjing Hu, Baorui Liu, Li Xie
Summary: Cervical cancer is a common malignancy among females, and virus-targeted immune therapy, including vaccines and adoptive immune cell therapy, has attracted attention. Research has shown that adoptive tumor infiltrating lymphocytes (TILs) cell therapy has the potential to control advanced disease progression and has demonstrated sustained therapeutic effects in some cases.
HUMAN VACCINES & IMMUNOTHERAPEUTICS
(2022)
Article
Oncology
Jason Chesney, Karl D. Lewis, Harriet Kluger, Omid Hamid, Eric Whitman, Sajeve Thomas, Martin Wermke, Mike Cusnir, Evidio Domingo-Musibay, Giao Q. Phan, John M. Kirkwood, Jessica C. Hassel, Marlana Orloff, James Larkin, Jeffrey Weber, Andrew J. S. Furness, Nikhil Khushalani, Theresa Medina, Michael E. Egger, Friedrich Graf Finckenstein, Madan Jagasia, Parameswaran Hari, Giri Sulur, Wen Shi, Xiao Wu, Amod Sarnaik
Summary: Investigational lifileucel demonstrated clinically meaningful activity in heavily pretreated patients with advanced melanoma and high tumor burden, indicating the potential benefit of this therapy in patients with limited treatment options in ICI-refractory disease.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Immunology
Sarah Bazargan, Brittany Bunch, Awino Maureiq E. Ojwang', Jamie Blauvelt, Annick Landin, Johannes Ali, Dominique Abrahams, Cheryl Cox, Amy M. Hall, Matthew S. Beatty, Michael Poch, Katarzyna A. Rejniak, Shari Pilon-Thomas
Summary: MDSCs are present in bladder tumors and suppress T cells. Gemcitabine can be used to deplete lymphocytes in bladder tumors and precondition the microenvironment for intravesical adoptive cell therapy (ACT). Combination treatment with gemcitabine and OT-I T cells showed sustained anti-tumor responses in orthotopic bladder tumor models.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Immunology
Ahmet Murat Aydin, MacLean Hall, Brittany L. Bunch, Holly Branthoover, Zachary Sannasardo, Amy Mackay, Matthew Beatty, Amod A. Sarnaik, John E. Mullinax, Philippe E. Spiess, Shari Pilon-Thomas
Summary: This study demonstrated successful expansion of tumor-reactive TIL from penile cancer patients, supporting the development of ACT strategies using TIL for the treatment of advanced and recurrent penile cancer.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2021)
Article
Oncology
Troels Holz Borch, Katja Harbst, Aynal Haque Rana, Rikke Andersen, Evelina Martinenaite, Per Kongsted, Magnus Pedersen, Morten Nielsen, Julie Westerlin Kjeldsen, Anders Handrup Kverneland, Martin Lauss, Lisbet Rosenkrantz Holmich, Helle Hendel, Ozcan Met, Goran Jonsson, Marco Donia, Inge Marie Svane
Summary: Priming with vemurafenib before TIL infusion in patients with metastatic melanoma showed promising results in inducing clinical responses and could potentially improve treatment efficacy. Further studies are needed to validate these findings and optimize the use of vemurafenib in combination with TIL therapy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Editorial Material
Oncology
Stephanie A. Blankenstein, Johannes J. Bonenkamp, Maureen J. B. Aarts, Franchette W. P. J. van den Berkmortel, Christian U. Blank, Willeke A. M. Blokx, Marye J. Boers-Sonderen, Alfons J. M. van den Eertwegh, Margreet G. Franken, Jan Willem B. de Groot, John B. A. G. Haanen, Geke A. P. Hospers, Ellen W. Kapiteijn, Olivier J. van Not, Djura Piersma, Rozemarijn S. van Rijn, Karijn P. M. Suijkerbuijk, Astrid A. M. van der Veldt, Gerard Vreugdenhil, Hans M. Westgeest, Michel W. J. M. Wouters, Alexander C. J. van Akkooi
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Oncology
Stephanie A. Blankenstein, Johannes J. Bonenkamp, Maureen J. B. Aarts, Franchette W. P. J. van den Berkmortel, Christian U. Blank, Willeke A. M. Blokx, Marye J. Boers-Sonderen, Alfons J. M. van den Eertwegh, Margreet G. Franken, Jan Willem B. de Groot, John B. A. G. Haanen, Geke A. P. Hospers, Ellen W. Kapiteijn, Olivier J. van Not, Djura Piersma, Rozemarijn S. van Rijn, Karijn P. M. Suijkerbuijk, Astrid A. M. van der Veldt, Gerard Vreugdenhil, Hans M. Westgeest, Michel W. J. M. Wouters, Alexander C. J. van Akkooi
Summary: In patients with unresectable stage IIIC or IV melanoma, there was no significant difference in disease outcome for those previously staged with SLNB compared to those who were not staged with SLNB prior to the availability of adjuvant systemic therapy.
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Oncology
Eva Ellebaek, Aimilia Schina, Henrik Schmidt, Charlotte Aaquist Haslund, Lars Bastholt, Inge Marie Svane, Marco Donia
Summary: This study found that initiation of immunotherapy in summer is associated with prolonged survival in patients with BRAF wild-type melanoma in Denmark.
PIGMENT CELL & MELANOMA RESEARCH
(2023)
Editorial Material
Oncology
Neel Maria Helvind, Marie Brinch-Moller Weitemeyer, Annette Hougaard Chakera, Helle Westergren Hendel, Eva Ellebaek, Inge Marie Svane, Mette Wanscher Kjaerskov, Sophie Bojesen, Helle Skyum, Soren Kjaer Petersen, Lars Bastholt, Christoffer Johansen, Pernille Envold Bidstrup, Lisbet Rosenkrantz Holmich
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Oncology
Inna M. Chen, Marco Donia, Christopher A. Chamberlain, Agnete W. P. Jensen, Arianna Draghi, Susann Theile, Kasper Madsen, Jane P. Hasselby, Anders Toxvaerd, Estrid Hogdall, Torben Lorentzen, Eva E. Wilken, Poul Geertsen, Inge M. Svane, Julia S. Johansen, Dorte Nielsen
Summary: The combination of ipilimumab, nivolumab, tocilizumab, and SBRT did not meet the expected criteria for treating pancreatic cancer.
EUROPEAN JOURNAL OF CANCER
(2023)
Letter
Gastroenterology & Hepatology
Emilie Dahl, Osama Abed, Jorgen Agnholt, Jacob Bjerrum, Anders Dige, Jens Kjeldsen, Inge Svane, Marco Donia, Jakob Seidelin
Summary: This article is linked to Dahl et al papers. To view these articles, visit...
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Article
Oncology
Stefanie L. Groenland, J. M. Janssen, C. M. Nijenhuis, N. de Vries, H. Rosing, S. Wilgenhof, J. V. van Thienen, J. B. A. G. Haanen, C. U. Blank, J. H. Beijnen, A. D. R. Huitema, N. Steeghs
Summary: The study examined the relationship between drug exposure and efficacy and toxicity in melanoma patients treated with dabrafenib plus trametinib. Results showed that trametinib exposure was related to survival, with a threshold of 15.6ng/mL. Patients with trametinib concentrations at or above this threshold had a significantly longer median overall survival compared to those with concentrations below the threshold. Exposure to dabrafenib and trametinib was not associated with clinically relevant toxicities.
CANCER CHEMOTHERAPY AND PHARMACOLOGY
(2023)
Review
Oncology
Tine J. Monberg, Troels H. Borch, Inge M. Svane, Marco Donia
Summary: Treatment with tumor-infiltrating lymphocytes (TIL) has been proven to be safe, feasible, and effective for patients with metastatic melanoma. However, its implementation on a larger scale is currently limited due to the lack of regulatory approvals. This review discusses the current knowledge of TIL therapy and addresses the practical, logistic, and economic challenges associated with its widespread implementation.
CLINICAL CANCER RESEARCH
(2023)
Article
Oncology
Arianna Draghi, Mario Presti, Agnete W. P. Jensen, Christopher A. Chamberlain, Benedetta Albieri, Anne-Christine K. Rasmussen, Mads H. Andersen, Michael D. Crowther, Inge Marie Svane, Marco Donia
Summary: Our study demonstrates that exploiting tumor-specific cytotoxic CD4(+) TILs could help overcome resistance to ICB mediated by IFN gamma-signaling loss in MHCIIconst(+) melanomas.
CLINICAL CANCER RESEARCH
(2023)
Article
Immunology
Sofie Kirial Mork, Per Kongsted, Marie Christine Wulff Westergaard, Benedetta Albieri, Joachim Stoltenborg Granhoj, Marco Donia, Evelina Martinenaite, Morten Orebo Holmstroem, Kasper Madsen, Anders H. Kverneland, Julie Westerlin Kjeldsen, Rikke Boedker Holmstroem, Cathrine Lund Lorentzen, Nis Norgaard, Lars Vibe Andreasen, Grith Kroyer Wood, Dennis Christensen, Michael Schantz Klausen, Sine Reker Hadrup, Per Thor Straten, Mads Hald Andersen, Inge Marie Svane
Summary: This study evaluated the tolerability and safety of a vaccine using Bcl-XL-peptide and CAF((R))09b as an adjuvant in patients with hormone-sensitive prostate cancer. The optimal route of administration and vaccine immunogenicity were also assessed. The vaccine was found to be feasible and safe, and it was able to induce immune responses. IP administration led to earlier and stronger vaccine-specific immune responses compared to IM administration.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Immunology
Jacob Handlos Grauslund, Morten Orebo Holmstrom, Evelina Martinenaite, Thomas Landkildehus Lisle, Hannah Jorinde Glockner, Daniel El Fassi, Uffe Klausen, Rasmus E. J. Mortensen, Nicolai Jorgensen, Lasse Kjaer, Vibe Skov, Inge Marie Svane, Hans Carl Hasselbalch, Mads Hald Andersen
Summary: The study tested the safety and efficacy of dual vaccination with ARG1- and PD-L1-derived peptides in JAK2 V617F-mutated MPN patients. The vaccines were found to be safe and induced strong T-cell responses in all patients, indicating their potential as a treatment option.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Immunology
Thomas Morgan Hulen, Christina Friese, Nikolaj Pagh Kristensen, Joachim Stoltenborg Granhoj, Troels Holz Borch, Marlies J. W. Peeters, Marco Donia, Mads Hald Andersen, Sine Reker Hadrup, Inge Marie Svane, Ozcan Met
Summary: Checkpoint inhibition (CPI) therapy and adoptive cell therapy with autologous tumor-infiltrating lymphocytes (TIL-based ACT) have shown to be highly effective immunotherapies for metastatic melanoma treatment. In this study, we investigated the changes in TIL qualities when the ex vivo microenvironment of intact tumor fragments were modulated with checkpoint inhibitors targeting PD-1 and CTLA-4. We found that unmodified TILs from CPI-resistant individuals could be produced, were terminally differentiated, and capable of responding to tumor. Furthermore, we confirmed the specificity of TILs to highly responding tumor antigens and identified the contribution of specific CD39(+)CD69(+) terminally differentiated populations.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Genetics & Heredity
Annie Borch, Anne-Mette Bjerregaard, Vinicius Araujo Barbosa de Lima, Olga Ostrup, Christina Westmose Yde, Aron Charles Eklund, Morten Mau-Sorensen, Carolina Barra, Inge Marie Svane, Finn Cilius Nielsen, Samuel A. Funt, Ulrik Lassen, Sine Reker Hadrup
Summary: Immune checkpoint inhibition has revolutionized cancer treatment, but only a fraction of patients respond to this therapy. Identifying biomarkers is crucial for selecting patients who will benefit from treatment. Our study revealed that patients with higher neoepitope load, higher expression of T cell signatures, and higher PD-L2 expression had better clinical outcomes. Combining these biomarkers improves prediction of treatment efficacy.
FRONTIERS IN GENETICS
(2023)
Article
Cell Biology
Tetje C. van der Sluis, Guillaume Beyrend, Esme T. I. van der Gracht, Tamim Abdelaal, Simon P. Jochems, Robert A. Belderbos, Thomas H. Wesselink, Suzanne van Duikeren, Floortje J. van Haften, Anke Redeker, Laura F. Ouboter, Elham Beyranvand Nejad, Marcel Camps, Kees L. M. C. Franken, Margot M. Linssen, Peter Hohenstein, Noel F. C. C. de Miranda, Hailiang Mei, Adriaan D. Bins, John B. A. G. Haanen, Joachim G. Aerts, Ferry Ossendorp, Ramon Arens
Summary: Immune checkpoint therapy (ICT) has the potential to eliminate cancer, but the underlying mechanisms determining its effectiveness are not fully understood. By using high-dimensional single-cell profiling, this study investigates if the T cell landscape in peripheral blood can predict responses to combinatorial targeting of the OX40 costimulatory and PD-1 inhibitory pathways. The findings reveal dynamic activation states of therapy-responsive T cells and emphasize the importance of NK cell receptors and chemokine receptors in therapy-induced anti-tumor immunity.
CELL REPORTS MEDICINE
(2023)
Article
Biochemistry & Molecular Biology
Garry Dolton, Cristina Rius, Aaron Wall, Barbara Szomolay, Valentina Bianchi, Sarah A. E. Galloway, Md Samiul Hasan, Theo Morin, Marine E. Caillaud, Hannah L. Thomas, Sarah Theaker, Li Rong Tan, Anna Fuller, Katie Topley, Mateusz Legut, Meriem Attaf, Jade R. Hopkins, Enas Behiry, Joanna Zabkiewicz, Caroline Alvares, Angharad Lloyd, Amber Rogers, Peter Henley, Christopher Fegan, Oliver Ottmann, Stephen Man, Michael D. Crowther, Marco Donia, Inge Marie Svane, David K. Cole, Paul E. Brown, Pierre Rizkallah, Andrew K. Sewell
Summary: Tumor-infiltrating lymphocyte therapy can activate T cells of the immune system to target and eliminate solid cancers. Through the use of combinatorial peptide libraries and a proteomic database, the antigen specificities of persistent cancer-specific T cell receptors (TCRs) were identified after successful therapy for stage IV malignant melanoma. These TCRs were capable of targeting multiple tumor types through specific epitopes, and the atomic structures revealed the importance of a shared recognition motif. The ability of these multi-epitope targeting T cells to recognize cancer cells surpasses the recognition of individual epitopes, making them promising candidates for future immunotherapies.
Article
Oncology
Andra S. Martinikova, Miroslav Stoyanov, Anna Oravetzova, Yannick P. Kok, Shibo Yu, Jana Dobrovolna, Pavel Janscak, Marcel van Vugt, Libor Macurek
Summary: Oncogene-induced replication stress is a major cause of genome instability in cancer cells. This study reveals that increased activity of PPM1D exacerbates replication stress caused by cyclin E1 overexpression, leading to abnormal cell cycle progression and accumulation of DNA copy number alterations. Pharmacological inhibition of PPM1D can alleviate replication stress-induced genome instability.
MOLECULAR ONCOLOGY
(2024)
Article
Oncology
Alamelu G. Bharadwaj, Meghan E. McLean, Margaret L. Dahn, Hannah F. Cahill, Marie-Claire D. Wasson, Raj Pranap Arun, Olivia L. Walker, Brianne M. Cruickshank, Wasundara Fernando, Jaganathan Venkatesh, Penelope J. Barnes, Gillian Bethune, Gregory Knapp, Lucy K. Helyer, Carman A. Giacomantonio, David M. Waisman, Paola Marcato
Summary: ALDH1A3 regulates the plasminogen activation pathway to promote breast cancer metastasis. Co-expression of ALDH1A3 and tPA is associated with TNBC subtype, high tumor grade, and recurrent metastatic disease.
MOLECULAR ONCOLOGY
(2024)
Article
Oncology
Nayela N. Chowdhury, Yi Yang, Ananya Dutta, Michelle Luo, Zimu Wei, Sara R. Abrahams, Alexey S. Revenko, Fenil Shah, Lindsey A. Miles, Robert J. Parmer, Bas de Laat, Alisa S. Wolberg, James P. Luyendyk, Melissa L. Fishel, Matthew J. Flick
Summary: Pancreatic ductal adenocarcinoma (PDAC) is a highly fatal metastatic disease associated with robust activation of the coagulation and fibrinolytic systems. Primary fibrinolytic protease plasminogen promotes PDAC tumor growth and metastatic potential through engaging plasminogen receptors on tumor cells.
MOLECULAR ONCOLOGY
(2024)
Article
Oncology
Nuria Gendrau-Sanclemente, Agnes Figueras, Kristina Gracova, Alvaro Lahiguera, Elisenda Alsina-Sanchis, Juan A. Marin-Jimenez, August Vidal, Xavier Matias-Guiu, Sergi Fernandez-Gonzalez, Marc Barahona, Lola Marti, Jordi Ponce, Francesc Vinals
Summary: High-grade serous ovarian cancer (HGSOC), the deadliest gynecological malignancy, spreads through transcoelomic dissemination. This study reveals that platelet-derived growth factor receptor beta (PDGFRβ) is essential for the formation of tumorspheres in HGSOC. Inhibition of PDGFRβ blocks the clustering of ovarian cancer cells and prevents peritoneal dissemination.
MOLECULAR ONCOLOGY
(2024)
